Latent membrane protein 1, tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF-2, TRAF-3, and nuclear factor kappa B expression in posttransplantation lymphoproliferative disorders.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: College of American Pathologists Country of Publication: United States NLM ID: 7607091 Publication Model: Print Cited Medium: Internet ISSN: 1543-2165 (Electronic) Linking ISSN: 00039985 NLM ISO Abbreviation: Arch Pathol Lab Med Subsets: MEDLINE
    • Publication Information:
      Publication: Northfield, Ill. : College of American Pathologists
      Original Publication: Chicago, American Medical Assn.
    • Subject Terms:
      Lymphoproliferative Disorders/*etiology ; Lymphoproliferative Disorders/*metabolism ; NF-kappa B/*metabolism ; Proteins/*metabolism ; Viral Matrix Proteins/*metabolism; Bone Marrow Transplantation/adverse effects ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Lymphoproliferative Disorders/virology ; NF-kappa B/immunology ; Organ Transplantation/adverse effects ; Proteins/immunology ; RNA, Viral/analysis ; TNF Receptor-Associated Factor 1 ; TNF Receptor-Associated Factor 2 ; TNF Receptor-Associated Factor 3 ; Viral Matrix Proteins/genetics
    • Abstract:
      Context: Most posttransplantation lymphoproliferative disorders (PTLDs) are associated with Epstein-Barr virus (EBV) infection. The EBV latent membrane protein 1 (LMP-1) is important in the transformation of B lymphocytes through its interaction with intracellular tumor necrosis factor receptor-associated factors (TRAFs) that, in turn, can activate transcription factors such as nuclear factor kappa B (NFkappaB) and Jun-N-kinase. Of the 6 members of the TRAF family, TRAF-1, TRAF-2, and TRAF-3 are most commonly associated with LMP-1. Recently, it has been suggested that LMP-1-induced TRAF activation is important in the pathogenesis of PTLDs.
      Objective: To characterize the expression patterns of these proteins in PTLDs, we studied a series of well-characterized cases for expression of LMP-1, TRAF-1, TRAF-2, TRAF-3, and NFkappaB by immunohistochemical analysis.
      Methods: A total of 27 specimens from 25 patients were analyzed for LMP-1, TRAF-1, TRAF-2, TRAF-3, and NFkappaB (active form) by immunohistochemical analysis. Expression of EBV-encoded RNA (EBER) was evaluated by in situ hybridization. Correlation between the expression of the different markers was performed using the Mantel-Haenszel chi(2) test. Cox proportional hazards analysis and Kaplan-Meier analysis with log-rank testing were used to analyze antigen expression and clinical outcome.
      Results: Ninety-six percent of PTLDs expressed NFkappaB, 74% to 84% expressed TRAFs, 78% expressed EBER, and 77% expressed LMP-1. TRAF-1, TRAF-2, and TRAF-3 expression did not correlate with either EBER or LMP-1 expression. TRAF-2, but not TRAF-1 or TRAF-3, expression correlated with NFkappaB expression (P =.02).
      Conclusions: These results suggest that TRAF molecules and active NFkappaB are expressed in PTLDs regardless of EBV positivity. Given the association of TRAF-2 and active NFkappaB expression, TRAF-2 may play an important role in regulating this transcription factor in PTLD.
    • Accession Number:
      0 (EBV-associated membrane antigen, Epstein-Barr virus)
      0 (NF-kappa B)
      0 (Proteins)
      0 (RNA, Viral)
      0 (TNF Receptor-Associated Factor 1)
      0 (TNF Receptor-Associated Factor 2)
      0 (TNF Receptor-Associated Factor 3)
      0 (Viral Matrix Proteins)
    • Publication Date:
      Date Created: 20031003 Date Completed: 20031104 Latest Revision: 20210527
    • Publication Date:
      20221213
    • Accession Number:
      10.5858/2003-127-1335-LMPTNF
    • Accession Number:
      14521460